Chaves

Researchers are evaluating the effectiveness, safety, and patient-reported outcomes of standard antimyeloma treatments in people with relapsed andor refractory multiple myeloma over a 24-month period. This observational study focuses on participants who have previously received treatment and aims to understand real-life clinical practice outcomes. The study is sponsored by Janssen Pharmaceutica N.V., Belgium, and collects data from routine medical care without interventional treatments. Participants with relapsedrefractory multiple myeloma receiving standard antimyeloma treatments as part of their regular clinical care will be observed. The primary source of data will be the participants medical records. There is no experimental drug or placebo involved. The study includes different observation periods to assess various outcomes related to response rates, disease progression, and quality of life. During the study, researchers will review participants medical records and track a wide range of outcomes including overall response rate, progression-free survival, adverse events, and health-related quality of life using validated questionnaires. The study follows participants for up to 52 months, monitoring treatment responses, safety, and patient-reported oral toxicities. This long-term observation helps to understand treatment effectiveness and patient experiences in everyday clinical settings.